WEST PHARMACEUTICAL SERVICES INC
Historical Data
View all| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 3, 2026 | $115.38 | $117.79 | $114.23 | $116.76 | 7.75M |
| Jul 2, 2026 | $120.39 | $125.56 | $110.06 | $115.38 | 10.74M |
| Jul 1, 2026 | $111.48 | $128.17 | $105.37 | $120.39 | 7.88M |
| Jun 30, 2026 | $118.16 | $121.09 | $108.30 | $111.48 | 6.50M |
| Jun 29, 2026 | $122.69 | $128.53 | $114.48 | $118.16 | 7.94M |
| Jun 28, 2026 | $124.40 | $126.86 | $120.56 | $122.69 | 10.97M |
| Jun 27, 2026 | $124.01 | $125.00 | $123.19 | $124.40 | 11.38M |
| Jun 26, 2026 | $129.16 | $130.13 | $121.55 | $124.01 | 6.76M |
Company Overview
WEST PHARMACEUTICAL SERVICES INC operates in the communication services space within the Communication Services sector. The company generates the majority of its revenue from operating momentum, and has built a durable competitive position through scale, brand, and continued reinvestment. It serves customers globally and is headquartered in the United States. Reported figures on this page are generated for demonstration and are not investment advice.
Leadership
Board 10 · Independent 8 of 10| Date | Firm | Target | Rating |
|---|---|---|---|
| Jun 26 | Goldman Sachs | $151.38 | Neutral |
| Jun 11 | Mizuho | $118.18 | Hold |
| Jun 11 | Wedbush | $176.29 | Hold |
| May 31 | Goldman Sachs | $200.53 | Strong Buy |
| May 21 | Truist Financial | — | Reduce |
| May 8 | Mizuho | $176.93 | Hold |
Politician Trades
View allWhat's Happening Right Now
- Sep 18, 2026 · Market Reaction ↗ — West Pharmaceutical shares slipped following a Fed-driven market drop but the company's Q2 2026 results reportedly remained strong.
- Sep 14, 2026 · Analyst ↗ — An analysis highlighted robust growth at West Pharmaceutical along with a suggested 17% upside for the stock.
- Sep 15, 2026 · Insider Activity ↗ — Insider Annette Favorite exercised stock options and sold shares in September 2026.
- Sep 10, 2026 · Compensation ↗ — CEO Michel Lagarde was granted new stock options and RSUs in September 2026.
- Sep 11, 2026 · Insider Activity ↗ — A senior VP sold approximately $2.77 million worth of West Pharmaceutical stock.
Snapshot
West Pharmaceutical generated $3.07B in revenue for FY2025, up 6.3% year-over-year, with a gross margin of 35.9%. Net income came in at $493.70M, a 16.1% net margin, though reported operating income was notably low at $1.00M. The company invested $74.30M in R&D, roughly 2% of revenue, while generating strong operating cash flow of $754.80M against capital expenditures of $285.90M, yielding free cash flow of $468.90M. The balance sheet remains solid with $791.30M in cash and equivalents versus total debt of $202.80M.
Bottom Line
West Pharmaceutical shows healthy revenue growth, strong net margins, and robust free cash flow generation with a conservative balance sheet holding more cash than debt. However, the strikingly low reported operating income of $1.00M against a 16.1% net margin suggests a disconnect worth investigating further, possibly tied to non-operating items. Recent insider selling, including a CEO equity grant and a $2.77M VP sale, contrasts with bullish analyst commentary pointing to potential upside, leaving investors to weigh fundamental cash-flow strength against near-term insider signals.